These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12604663)

  • 1. Drugs targeting Alzheimer's disease: some things old and some things new.
    Michaelis ML
    J Pharmacol Exp Ther; 2003 Mar; 304(3):897-904. PubMed ID: 12604663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease pathogenesis and therapeutic interventions.
    Parihar MS; Hemnani T
    J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options in Alzheimer's disease.
    Moreira PI; Zhu X; Nunomura A; Smith MA; Perry G
    Expert Rev Neurother; 2006 Jun; 6(6):897-910. PubMed ID: 16784412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide.
    Pangalos MN; Jacobsen SJ; Reinhart PH
    Biochem Soc Trans; 2005 Aug; 33(Pt 4):553-8. PubMed ID: 16042543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of amyloid beta peptide 42 in Alzheimer's disease.
    Findeis MA
    Pharmacol Ther; 2007 Nov; 116(2):266-86. PubMed ID: 17716740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention.
    Eckman EA; Eckman CB
    Biochem Soc Trans; 2005 Nov; 33(Pt 5):1101-5. PubMed ID: 16246055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid inhibitors and Alzheimer's disease.
    Xia W
    Curr Opin Investig Drugs; 2003 Jan; 4(1):55-9. PubMed ID: 12625030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretases as therapeutic targets for Alzheimer's disease.
    Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
    Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway.
    Hook VY; Reisine TD
    J Neurosci Res; 2003 Nov; 74(3):393-405. PubMed ID: 14598316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
    Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
    J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease modifying therapy for AD?
    Golde TE
    J Neurochem; 2006 Nov; 99(3):689-707. PubMed ID: 17076654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors.
    Giovannini MG; Scali C; Prosperi C; Bellucci A; Pepeu G; Casamenti F
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):31-40. PubMed ID: 14552702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol and Alzheimer's disease--is there a relation?
    Sjögren M; Mielke M; Gustafson D; Zandi P; Skoog I
    Mech Ageing Dev; 2006 Feb; 127(2):138-47. PubMed ID: 16332384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS; Rauw G; Baker GB; Kar S
    Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and development of BACE-1 inhibitors.
    Cumming JN; Iserloh U; Kennedy ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):536-56. PubMed ID: 15338962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secretases as therapeutic targets for the treatment of Alzheimer's disease].
    Dejaegere T; de Strooper B
    Verh K Acad Geneeskd Belg; 2004; 66(1):29-58; discussion 58-9. PubMed ID: 15074081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.